Lahner, Harald; Mathew, Annie; Klocker, Anna Lisa; Unger, Nicole; Theysohn, Jens; Rekowski, Jan; Joeckel, Karl-Heinz; Theurer, Sarah; Schmid, Kurt Werner; Herrmann, Ken; Fuehrer, Dagmar published the artcile< Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy>, Related Products of 112-63-0, the main research area is pancreatic neuroendocrine tumor streptozocin fluorouracil chemotherapy; 5-fluorouracil; Objective response; Pancreatic neuroendocrine tumor; Streptozocin; Survival.
The role of streptozocin-based chemotherapy (STZ CTx) in advanced, well-differentiated pancreatic neuroendocrine tumors (PanNET) and the best sequence of treatments in advanced PanNET are unclear. We examined the outcomes after STZ CTx in patients who had been selected according to the current therapeutic guidelines. Data from 50 PanNET patients consecutively treated with STZ CTx between 2010 and 2018 were analyzed. The endpoints of the study were the objective-response rate (ORR), progression-free survival (PFS), and overall survival (OS). STZ CTx was the first-line treatment in 54% of patients. The PanNET grades were as follows: 6% G1, 88% G2, and 6% well-differentiated G3. The ORR was 38%. Stable disease was the best response in 38% of patients and 24% showed progressive disease. Treatment was discontinued because of toxicity in one patient. Median PFS and OS were 12 (95% confidence interval (CI), 8.5-15.5) and 38 mo (95% CI, 20.4-55.6), resp. In the Kaplan-Meier anal., the median OS was 89 mo (95% CI, 34.9-143.1) for STZ CTx as first-line therapy compared with 22 mo (95% CI, 19.3-24.7; p = 0.001, log-rank test) for subsequent lines. Bone metastases neg. impacted survival (HR, 2.71, p = 0.009, univariate anal., HR, 2.64, p = 0.015, multivariate anal., and Cox regression). In patients selected according to current guidelines, PFS, and OS after STZ CTx were lower than previously reported, whereas ORR was unchanged. First-line treatment was pos. associated with OS and the presence of bone metastases was neg. associated with OS. Pre-treatment with targeted or peptide-receptor radionuclide therapy did not alter ORR, PFS, or OS.
Endocrine published new progress about Anemia. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Related Products of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics